Ciclesonide
Chemical compound
- AU: B3
administration
- R01AD13 (WHO) R03BA08 (WHO)
- AU: S4 (Prescription only)
- UK: POM (Prescription only)
- US: ℞-only
- 2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
- 126544-47-6 N
- 6918155
- 7469
- DB01410 Y
- 5293368 Y
- S59502J185
- D01703 Y
- ChEMBL1201164 N
- DTXSID9046659
- Interactive image
- O=C(OCC(=O)[C@]25O[C@@H](O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C6CCCCC6)C(C)C
- InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 Y
- Key:LUKZNWIVRBCLON-GXOBDPJESA-N Y
Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco[1] for hay fever in the US and Canada.
Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[2]
It was patented in 1990 and approved for medical use in 2005.[3] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[4] It is on the World Health Organization's List of Essential Medicines.[5]
See also
References
- ^ "Covis Pharma – Products".
- ^ Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–1664. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
- ^ "FDA News Release. FDA Approves New Treatment for Allergies". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Further reading
- Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3.
- v
- t
- e
- Antagonists: Aglepristone
- Ketoconazole
- Mifepristone
- Ulipristal acetate
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Glucocorticoid receptor modulators
- Mineralocorticoids and antimineralocorticoids
- List of corticosteroids